WHO halts trial of hydroxychloroquine, says drug not effective in COVID-19 treatment

World Health Organisation (WHO), on Wednesday, anunced that it will be stopping hydroxychloroquine (HCQ) arm of Solidarity Trial. UN organisation furr clarified that this 'decision applies only to conduct of Solidarity trial and does t apply to use or evaluation of hydroxychloroquine in pre or post-exposure prophylaxis in patients exposed to COVID-19'.

RE: WHO Welcomes Trial Results Of Dexamethasone, Congratulates UK Govt And Oxford

HCQ doesn't reduce mortality of COVID-19 patients

WHO stated that decision was taken based on evidence from Solidarity trial and UK’s Recovery trial. According to data procured from trials, 'hydroxychloroquine does t result in reduction of mortality of hospitalized COVID-19 patients when compared with standard of care'. This means that WHO will longer be conducting randomized tests of HCQ on patients. Those who are in middle of trial can choose to continue it or stop after consulting ir physician. 

Earlier this week, USA  Food and Drug ministration (FDA) withdrew emergency use authorisation of HCQ after concluding that y may t be effective to cure virus infections. FDA said its decision is based on new information, including clinical trial data results, that have led it to conclude that drugs may t be effective to treat COVID-19 and that its potential benefits for such use do t outweigh its kwn and potential risks.

RE: US FDA Withdraws Emergency Use Authorisation Of Chloroquine And Hydroxychloroquine

Or vaccines

Earlier, WHO's Director-General Dr. Tedros ham welcomed preliminary clinical trial results from United Kingdom that show dexamethasone, a steroid, can be lifesaving for coronavirus patients under ventilator or oxygen support. "This is first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support. This is great news and I congratulate Government of UK, University of Oxford, and many hospitals and patients in UK who have contributed to this lifesaving scientific breakthrough," he said.

RE: EU Governments Ban Use Of Hydroxychloroquine Drug For COVID-19 Patients

According to researchers, daily doses of dexamethasone could prevent deaths among one in eight ventilated patients and might save life of a patient out of total 25 patients that might be in need of a ventilator or intubation due to respiratory issues, team said, as per reports. However, a group of 4,000 patients who did t receive dos of drug h worsening symptoms, scientists reported.  

RE: Pause In WHO Hydroxychloroquine Testing